Sanofi ADR
I · AI-analyse
In het kort
Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].
Sanofi is a major French pharmaceutical company with $104,3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10,1 billion in free cash flow and a 5,55% dividend yield [Yahoo Finance].
Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].
Sentinellis-score
7,4/10
Matige zorgen
Marktkapitalisatie
$104,3B
Omzet (12 maanden)
EUR 46,7B
Uitleg
Hoe wij deze cijfers lezen
Begrijpelijke gidsen · geen account nodig
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LezenPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LezenAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LezenII · Recent nieuws
Wat de koers bewoog
5 berichten · gesorteerd op relevantie
- Macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- Macro2026-05-18
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Yahoo Finance
- Macro2026-05-18
A Look At Sanofi (ENXTPA:SAN) Valuation After Recent Share Price Weakness
Simply Wall St
- Macro2026-05-18
Sanofi Deepens AI And Alzheimer’s Research While Shares Trade Below Targets
Simply Wall St
- Macro2026-05-19
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Yahoo Finance
Premium · gratis met elk account
The stock dropped 9% over the past month and has struggled over the past year, signaling investor concern about near-term performance despite longer-term gains [Simply Wall St]
Risico's
5
Kansen
6
Waarschuwingssignalen
2
Leiding
10
Nog 12 bevindingen in het volledige rapport — gratis met elk account.
Ontgrendel de volledige analyse van Sanofi ADR
Maak een gratis account voor het volledige AI-rapport met bronvermelding in de tekst.
- 5 risico's, 6 kansen en 2 waarschuwingssignalen — elk met zijn bron
- Meer dan 100 financiële cijfers met grafieken en vergelijkingen
- Volledige nieuwssamenvattingen met bronlinks
- Directie en beloning
III · Vergelijkbare bedrijven
Misschien ook interessant
Zelfde sector · Gezondheidszorg — of vergelijkbare financiële gezondheid
Op je volglijst zetten?